Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, College of Pharmacy, Chongqing Medical University, Chongqing, 400016, P. R. China.
Centre for Lipid Research & Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400016, P. R. China.
Adv Sci (Weinh). 2023 Jul;10(19):e2300502. doi: 10.1002/advs.202300502. Epub 2023 Apr 21.
The broad application of clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome editing tools is hindered by challenges in the efficient delivery of its two components into specific cells and intracytoplasmic release. Herein, a novel copolymer for delivery of Cas9-mRNA/ single-guide RNA (Cas9-mRNA/sgRNA) in vitro and vivo, using carboxylesterase-responsive cationic triadic copolymeric nanoparticles targeted proprotein convertase subtilisin/kexin type 9 (PCSK9) for hyperlipidemia amelioration is reported. A dimethyl biguanide derivative is designed and synthesized to form cationic block, and copolymerization onto prepolymer with propyl methacrylate, to fabricate a triadic copolymer mPEG-b-P(Met/n-PMA). The copolymer can self-assemble with Cas9-mRNA/sgRNA, indicating the excellent potential of nanoparticles to form a delivery carrier. This vehicle can efficiently release RNA in response to the hepatocytes carboxylesterase for genome editing. It was demonstrated that the mPEG-b-P(Met/n-PMA)/Cas9 mRNA/sgRNA nanoparticles effectively accumulated in hepatocytes, lead to the inhibition of PCSK9, and lowered the levels of Low-density lipoprotein cholesterol and total cholesterol in mouse serum down 20% of nontreatment. Interestingly, the nanoparticles even enable multiple functions in the regulation of blood glucose and weight. This study establishes a novel method to achieve complex CRISPR components stable loading, safe delivery, and fixed-point release, which expand the application of CRISPR delivery systems.
CRISPR/Cas9 基因组编辑工具的广泛应用受到将其两个组件有效递送至特定细胞和细胞内释放的挑战的阻碍。在此,我们报道了一种新型共聚物,用于体外和体内递送 Cas9-mRNA/单指导 RNA(Cas9-mRNA/sgRNA),使用针对载脂蛋白转化酶枯草溶菌素/激肽释放酶 9(PCSK9)的羧酸酯酶响应性阳离子三嵌段共聚物纳米颗粒靶向蛋白水解酶 9(PCSK9)用于改善高血脂症。设计并合成了一种二甲双胍衍生物以形成阳离子嵌段,并与丙基甲基丙烯酸酯预聚物共聚,以制备三嵌段共聚物 mPEG-b-P(Met/n-PMA)。该共聚物可以与 Cas9-mRNA/sgRNA 自组装,表明纳米粒子具有形成递送载体的优异潜力。该载体可以有效地响应肝细胞羧酸酯酶释放 RNA 进行基因组编辑。结果表明,mPEG-b-P(Met/n-PMA)/Cas9 mRNA/sgRNA 纳米颗粒可有效积聚在肝细胞中,导致 PCSK9 抑制,并使小鼠血清中 LDL 胆固醇和总胆固醇水平降低 20%,而非治疗组。有趣的是,纳米颗粒甚至可以实现调节血糖和体重的多种功能。本研究建立了一种新方法,可实现复杂的 CRISPR 组件的稳定负载、安全递送和定点释放,从而扩展了 CRISPR 递送系统的应用。